The first biomarker used for PCa screening was prostatic acid phosphatase (PAP) [3], the use of which was limited in the clinic once screening with the prostate-specific antigen (PSA) was initiated in 1979 [4]. The gene discussed is ACP3; the disease is posterior cortical atrophy.